Analysts at UBS initiated coverage on Esperion Therapeutics, Inc. ESPR with a Buy rating.
The target price for Esperion Therapeutics is set to $140.
Esperion Therapeutics shares have gained 525.68% over the past 52 weeks, while the S&P 500 index has surged 9.36% in the same period.
Esperion Therapeutics' shares rose 4.21% to $96.50 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in